1. Home
  2. CPRT vs ICUCW Comparison

CPRT vs ICUCW Comparison

Compare CPRT & ICUCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CPRT
  • ICUCW
  • Stock Information
  • Founded
  • CPRT 1982
  • ICUCW N/A
  • Country
  • CPRT United States
  • ICUCW United States
  • Employees
  • CPRT N/A
  • ICUCW 19
  • Industry
  • CPRT Other Specialty Stores
  • ICUCW Biotechnology: Pharmaceutical Preparations
  • Sector
  • CPRT Consumer Discretionary
  • ICUCW Health Care
  • Exchange
  • CPRT Nasdaq
  • ICUCW Nasdaq
  • Market Cap
  • CPRT N/A
  • ICUCW N/A
  • IPO Year
  • CPRT 1994
  • ICUCW 2021
  • Fundamental
  • Price
  • CPRT $50.80
  • ICUCW $0.03
  • Analyst Decision
  • CPRT Buy
  • ICUCW
  • Analyst Count
  • CPRT 2
  • ICUCW 0
  • Target Price
  • CPRT $55.50
  • ICUCW N/A
  • AVG Volume (30 Days)
  • CPRT 6.7M
  • ICUCW N/A
  • Earning Date
  • CPRT 05-22-2025
  • ICUCW N/A
  • Dividend Yield
  • CPRT N/A
  • ICUCW N/A
  • EPS Growth
  • CPRT 5.62
  • ICUCW N/A
  • EPS
  • CPRT 1.51
  • ICUCW N/A
  • Revenue
  • CPRT $4,590,860,000.00
  • ICUCW N/A
  • Revenue This Year
  • CPRT $13.53
  • ICUCW N/A
  • Revenue Next Year
  • CPRT $9.23
  • ICUCW N/A
  • P/E Ratio
  • CPRT $33.64
  • ICUCW N/A
  • Revenue Growth
  • CPRT 10.21
  • ICUCW N/A
  • 52 Week Low
  • CPRT $48.05
  • ICUCW N/A
  • 52 Week High
  • CPRT $64.38
  • ICUCW N/A
  • Technical
  • Relative Strength Index (RSI)
  • CPRT 21.94
  • ICUCW N/A
  • Support Level
  • CPRT $61.66
  • ICUCW N/A
  • Resistance Level
  • CPRT $63.85
  • ICUCW N/A
  • Average True Range (ATR)
  • CPRT 1.33
  • ICUCW 0.00
  • MACD
  • CPRT -1.38
  • ICUCW 0.00
  • Stochastic Oscillator
  • CPRT 4.26
  • ICUCW 0.00

About ICUCW SeaStar Medical Holding Corporation Warrant

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

Share on Social Networks: